“Moreover, in the observational cohort study 88% of children treated with remestemcel-L had severe disease with highest mortality risk, defined by either IBMTR Grade C/D or Glucksberg Grade III/IV, whereas only 22% to 68% of patients in the other studies were considered to be severe.“
MSB - taking on the worst of the worst - and succeeding.
“Moreover, in the observational cohort study 88% of children...
-
- There are more pages in this discussion • 353 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
91.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $1.056B | |||
| Open | High | Low | Value | Volume |
| 90.5¢ | 92.5¢ | 89.5¢ | $2.757M | 3.048M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 23 | 160051 | 91.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 91.5¢ | 57366 | 36 |
View Market Depth
| Last trade - 14.57pm 08/08/2024 (20 minute delay) ? |
| MSB (ASX) Chart |